Unveiling a suspected dupilumab‐induced neuropathy in pediatric eosinophilic esophagitis-Reference-Cited by-同舟云学术

Unveiling a suspected dupilumab‐induced neuropathy in pediatric eosinophilic esophagitis

Published:2024-08 Issue:8 Volume:35 Page:
ISSN:0905-6157
Container-title:Pediatric Allergy and Immunology
language:en
Short-container-title:Pediatric Allergy Immunology

Author:

Gagnon Hugo¹^ORCID,Nguyen Cam‐Tu Émilie²,Hatami Afshin³,Bégin Philippe⁴,Grzywacz Kelly¹

Affiliation:

1. Pediatric Gastroenterology, Hepatology and Nutrition Centre Hospitalier Universitaire Sainte‐Justine Montreal Quebec Canada

2. Neurology Centre Hospitalier Universitaire Sainte‐Justine Montreal Quebec Canada

3. Dermatology Centre Hospitalier Universitaire Sainte‐Justine Montreal Quebec Canada

4. Allergy Centre Hospitalier Universitaire Sainte‐Justine Montreal Quebec Canada

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/pai.14217

Reference9 articles.

1. Global Incidence and Prevalence of Eosinophilic Esophagitis, 1976–2022: A Systematic Review and Meta-analysis

2. Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis

3. FDA approves first treatment for eosinophilic esophagitis a chronic immune disorder.2022https://www.fda.gov/news‐events/press‐announcements/fda‐approves‐first‐treatment‐eosinophilic‐esophagitis‐chronic‐immune‐disorder

4. Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

5. Dupixent FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE).2024https://www.sanofi.com/en/media‐room/press‐releases/2024/2024‐01‐25‐19‐30‐00‐2817342